In view of the vario us problems enco untered with the tradit ional methods of sec uring coc hlear impl ants-including dural tear and suture dissolu tionfo llow ing inf ection-we devised two alternate methods of p erfo rming this procedure. We use a titanium mesh or a Gore-Tex patch secured with two 4-mm screws tofix the receiver to the skull. No patient who has undergone either of these pro cedures at our institut ion has expe rienced any ofthe complications that are associated with the olde r silk, nylon, and Dacron sutures. Mo reove r, our two alternate methods are less technica lly difficult and can be performed in a shorter peri od of time.
Introduction
The incidenc e of electrode slippage in cochle ar implants was described by Webb et al in their review of impl ant compl ications worldwide.I They reviewed the outcomes of 4,969 nucleus implants in adult s and children and identified complications in 70 (1.4 %); 61 of the se patients ( 1.2%) experienced electrode migration and nine' (0.2 %) experienced recei ver migration. In a follo wup study, Hoffm an and Cohen reported that 42 of the se 70 patients (60%) required revision surgery.' In our experience, the traditional methods of securing the impl ant receiver with silk ties or nylon sutures are not optimal. In two of93 impl ant cases (2%) reviewed at our institution, wound infection led to an eros ion of the ties and movement of the rece iver under the sca lp flap, necessitatin g reimpl antation. In response to this problem , we devised two alterna te methods-using a titanium mesh or a Gore-Tex patch-of securing the cochlear implant receiver. From Titanium mesh. A hockey stick-shaped incision is made in the postauricular area, and a mastoidectomy via a facial recess approac h is performed . The cochlear implant bed is then drilled in the skull by egg-shelling the middle fossa periosteum . One hole each is made on the anterior and poster ior aspects of the implant receiver with a 1.7-mmdiameter cuffed 4-mm twist drill bit. A coc hleostomy is then perform ed, and the electrode is threaded into the coc hlea. Two 2.0 Leibinger 4-mm screws are used to hold a 5 x 5-cm , 0.3-mm-thick Leibin ger titanium mesh over the coc hlear implant and secure it in the depression made in the skull. The temp oralis fasc ia and skin are then clo sed in two layers (figure I).
Gore-Tex patch. The implant is placed in a manner similar to the one describ ed abo ve. After preparing the implant bed in the skull, two monoc ortic al holes are drilled-one anterior and one posteri or to the implantwith a 2.0-mm-diameter cuffed stra ight 4-mm drill bit. A 3 x 6-cm, O.4-mm-thick cardiovascul ar Gore-Tex patch is placed ove r the implant. While the patch is being stretched, holes are made in it over the screw sites with a Rosen needle. The patch is then sec ured to the skull with two 4mm screws placed through the holes made with the needle. The stretching of the patch in effect holds the implant sec urely against the skull (figure 2).
Discussion
The tradit ional meth ods of securing coc hlear implants are associated with complications . Graham et al described a method of using silk or Dacron ties to sec ure implants.' But in our experien ce, silk sutures eroded follow ing infection in two patient s. Furth erm ore, Dacron ties have been assoc iated with necrosis of the overl ying flap,' stitch abscess, and granulation tissue, which have caused implant exposure and external meatal skin ero sion.'
The se complications prompted efforts to develop a simpler method of securing impl ant s that would cause fewe r complications. Some of these methods concen- trated on fixing the electrode distally. Platinum wire ties have been used to secure the electrode to the incu s bar,' but this technique is difficult surgica lly and has the potential to dam age the electrode ." Ion omeric bon e ce-ment has also been used to secure the impl ant receiver and electrode.i? Although thi s method is very practical from a surg ical standpoint, it carries the risk of damaging the el ectrode, irritating the tissu es, and making re vision sur-
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The D ed o Extens ion -a sim ple but effec tive so lu tio n . Pregnancy: TeratogenicEffect s. PregnancyCate goryC: Moxifl oxacin .was not teratogenic when administered to pregnant rat s during orcanoceressat oral dosesashighas500mglkg lday or 0.24 times the max imum recommended human dose based on systemic exposure (AUC). but decreased fetal body weights and slightly delayed fetal skeletal developm ent (indicative of fetotoxici ty) were observed. Intravenous adm inistration of 20 mglkg/day (approximately equal to the maximum recommended human oral dosebased upon systemi c exposure)to pregnant rabbits duringorganogenesis resulted in decreasedfetal body weights anddelayedfetal skeletal ossifi cat ion. When rib andvertebral malformationswerecombined.there was anincreased fetal andliner incidenceof these effects. Signs of maternal toxicity in rabbits at this dose incl udedmortal ity, abortions. marked reductionO f loadconsumption. decr eased water intake. bod y weight lossand hypoactivity. There was noevidence of teratogenicity when pregnan t Cynomolgusmonk eys were givenoral doses ashighas100 mglkg/day (2.5 times themax imumrecommended human dose based uponsystemic exposure). Anincreased incidenceof smaller fetuses wasobserved at100 mglkglday. Inanoral pre-andpostnatal development study conductedinrats, effects observedat500mglkg/day included slightincr eases in duration of preg nancy andprenatal loss, reducedpupbirthwei ght and decreased neonatal survival. Treatment -related maternal mortality occurred during cesralion al 500mgJkgJday in thlsstudy. Since therearenoadequate orwell-controlled studies in pregnantwomen,max-ifloxacins~o ul d beused during pregnancy onl y ifthepotential benef it justif iesthe potential nsktothefetus. Nursing Mothers: Moxi floxacin isexcreted inthebreast milkof rats. Moxifloxacin may alsobeexcretedinhuman milk. Because of thepotential forserious adverse reactions in infa ntsnursing frommothers taking moxifloxacin, adecision should bemade whether to discontinue nursi ngor to discontinue thedrug , taking into account theimportance of the drugto themother. Pedi atricUse: Safety andeffectiveness in pedi atric pat ientsand adolescents less than 18 years ofage havenot been established. Moxifl oxacin causesarthropathy in juvenile animals. (SeeWARNINGS.) Geri atric Use: In controlled mult ipl e-dose clinical trials , 23% of patients receiving moxifloxacin wer e greater thanor equal to 65 years of age and 9% were greater thanor equal to 75years of age. The clinical trialdata demonstratethat thereis nodi fference in thesafety andeff icacyof moxifloxacin in patientsaged 65oroldercomparedto younger adul ts.
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ADVERSE REACTIDN S
Clinical efficacy trials enrolled over4900 moxifloxacin treated pati ents. of whom over4300 pat ients receivedthe 400mg dose. Mostadverse events reported in rnoxltloxacin trials were described asmild to moderate in sever ity andrequired notreatment. Moxifloxacinwasdiscontinued duetoadv erse reactionsthoughtto bedrug-related in 3.8% of pati ents. Adverse reactions, judged byinvestigators to beat least possibly drug-related, occurring in greater than or equal to 1% of moxif loxacin treatedpat ients were: nausea (8010), diarrhea (6010). dizziness (3%), headache (2%), abdominal pain (2%), vomit ing(2010), taste perversion (1%), abnormal liverfunctiontest(1%), anddyspepsia (1%). Addi tional events. judged by investigators to beat least possibly drug-related, that occur red in greater than 0.05% and less than 1% of moxif loxacin treated pat ientswere:
BODY 
In acute bacterial exacerbation of chronic bronchitis -5-day course
In acute bacterial sinusitis or community-acquired pneumonia of mild to moderate severity -10-day course Pharmacokineticstud iesbet ween rnoxltloxacln andother drugs thatprolongthe OT interval such ascisepride, erythromycin, ant ipsychotics, and tricyclic antidepressants have not been pertormed. An additiveeffect of moxifloxacin and these drugs cannot beexcluded, therefore moxifloxacin should be usedwith caution when given concurrently \'/ith thesedrugs.
Theeff ectof rnoxmoxacn onpatients with congenitalprolongation of theOTinterval has notbeen studied,however,it isexpected thatthese indi viduals may bemore susceptibletodrug-ind uced orprolongation. Becauseoflimited clinical experience, moxifloxacin should beused wi th cautionin patients with ongoing proarrhythmic conditions. such asclinically significant bradycardia,acutemyocardia l ischemia.
The magnitude of orprolongation mayincrease \'lith increasing concentrat ions of thedrug, thereforetherecommended dose should notbeexceeded. OT prolongation maylead toanincreased risk forventricular arrhythmiasincludi ngtorsade depontes, In 787patients with pai redvalid ECGs in Phase III clinical trial s, the mean ± SO effect of moxifloxacin 400mgon theOTc interval was 6 ± 26 msec. Nocardiovascular morbidity or mortalityattributable to OTcprolongation occur redwithmoxifloxacin treatmentinover 4000 patients, however certain predisposing conditions mayincrease therisk forventricular arrhythmias. The oral adm inistration of moxifloxacin caused lameness in imma ture dogs . Histopathological examination of theweight-bearingjointsofthese dogsrevealed permanent lesions of the cartilage. Related qunoone-class drugsalso produce erosions of cartilage of weight-bearing jointsand othersigns of arthropathy in immatureanimals of variousspecies. (SeeANIMALPHARMACOLOGY.) Convulsions have been report ed in patients receiving quinalanes. Ouinol ones mayalso cause central nervous system (CNS) events including: dizziness. confusion. tremors, hallucinations, depression. and, rar ely, suicidal thoughts oracts. These reactionsmay occurfallowing thefirst dose. If these reactions occu r in pati entsreceiving moxifloxacin, thedrugshould bediscontinued andappropriate measures instituted. As\'lith all qolnolones, moxilloxacin should be used with caution in patients with known or suspected CNS disorders (e.g. severe cerebral arteriosclerosis, epilepsy) or in thepresence of other risk factors thatmaypredispose toseizures orlowertheseizurethreshold. (See PRECAUTIONS: General, Informalionfor Patients, and ADVERSEREACTIONS.) Serious andoccasionally fatal hypersensitivity(anaphylactic) reactions,some followingthefirst dose, have been reported in patients receiving quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness. tingling, pharyngeal or facial edema. dyspnea, urticaria, anditching. Serious anaphylactic rea ctionsrequireimmediate emergencytreatmentwith epinephrine. Moxifloxacin should bediscontinued atthe first appearance of a skin rash or anyother signofhypersensitivity.Oxygen, intravenous stero ids, andairwaymanagement, includingintubation, may beadministered asindicated. Severeandsome times fatal events, some dueto hypersensitivity, andsome Of uncertain eti ology. have been reported in patients receiving therapy with all antibiotics.Theseevents may besever eandgenerall y occur following theadm inistration of multiple doses. Clinical manifestations may include oneor more of thefollowing: rash. fever , eosinophilia, jaundice, and hepatic necrosis. Pseu domembranous colitis has been report ed with nearly all antibacterial agentsandmayrange in severityfrom mildtolife-threat ening, Therefore, lt is import ant to consider this diagnosis in patients who present with diarrhea subse quent to the administration ofantibacterial agents. Treatment with antibacterialagents alters thenormal flora of the colon andmay permit overgro\'lth of clostridia. Studies indicate that a toxin produced by Clostridiumdifficileis oneprimary cause of "antibiotic-associated colitis.H Afterthediagnosis of pseudomembranous colitis has been established. therapeutic measures should be initi ated. Mildcas esof pseudom embranous coli tis usuallyrespond todrugdiscontinuationalone. Inmoderate to severecases. considerationshouldbegi vento man agement with fluidsand electrolytes, protein supp lementation, and treatment with an antibacterial drug clinically eff ecti ve aga instC. difficifecolitis. Althoughnot observedin moxitloxacin clinicaltrial s, Achillesandother tendon ruptures that required surgical repair or resultedin prolonged disability have been reported withquinolcnes. Moxifloxacin should bediscontinued if thepat ient experiencespain, inflammation, or rupture ofatendon. Appropriate culture and susceptibility tests should be performed before treatmentin order to isolate and identify organismscausing infection and to determinetheirsusceptibility to moxifloxacin. Therapy withAVELOXmay be initiated before results of these tests areknown: once results become avai lable. appropriate therapy should becontinued.
INDICATIONS ANO USAGE
CONTRAI NDICATIONS
Moxifloxacin is contraindicated in persons with a history of hypersensitivi ty to moxifloxacin oranymember of thequlno lone class ofantimicrobial agents. gery difficult." Cohen and Kuzm a reported on the use of a titanium cl ip that is fixed to the incu s ba r to secure the distal electrode." Balkany and Teli schi des cribed the splitbridge technique, in which a slot is dr illed thr ou gh the incu s bar." In this pro cedure, the ele ctrode is placed deep into the short process of the incus, wh ich fixes it." In a modification of this technique, a silicone-sheet sleeve has been used to protect the elect rode. One potenti al complica tion associ ated with this modification is that the electrode can slide inside the sheath ."
Mi gration of the receive r also present s a problem. Different methods of preparing the receiver bed and securing the rece iver ha ve been de sc rib ed . Hoffman and Cohen hav e advocated crea ting a deep well do wn to the dura and lea vin g an "i sland " of bone to prevent receiver migration in some children." However , this method can inc rea se the risk of dural tear, especially when drilling hol es in the surrounding dipl oic bon e to allow for the passin g of the sec uring sutures. Also, nearby bleeding could cause an epidural hem atoma.
The two methods that we have de scr ibed are different from tho se described by oth ers. We have found that electrod e migration can be prevented by sec ur ing the receiver and part of the pro xim al ele ct rode with a titanium me sh or Gore-Tex patch. At our institution , 170 patients have und ergone cochlear implantation in which the device wa s secured with a Gore-Tex patch, and IO ha ve received the mesh . During a mean foll owup of 12 months, we have found that electro de migr ation has not been a problem. Covering the implant with the titanium me sh or the Gore-Te x patch has not cau sed any difficulties in signal transmission to the rece iver. Titanium and Gore-Te x have a long track record of success ful use in human s by facial pl astic surg eons .10.11 Complications have been minimal. Th ese material s are well tolerated by tissues, do not migrate or fail , and are not oft en infected or extruded .!"!' Volume 80, Number 3
Another adv antage of the se two methods is that they carry a low er risk of du ral tear and cerebrospinal fluid lea kage. Using the cuffed drill bit s and limiting penetration with the 4-mm screws , we have no t experienced any cases of dural tears, subdura l or epidural hematomas, or cerebrospinal fluid leakage that were caused by the use of thi s technique. In addition, screw extru sion has not been a problem. Fin ally , the surg ica lly simpler methods we have de scribed require less time to perform than do the island-and-suture method . With the silk sutures, the avera ge len gth of time from the completion of the impl antbed dr illing to the secur ing of the de vice was 3 minutes and 35 seconds. With the Gore-Tex pat ch , the average time wa s 2 minutes. O verall, we prefer the Go re-Te x patch to the tit an ium me sh bec ause it is ea sier to use and less expensive.
